Coronavirus disease (COVID-19) vaccine
The present invention includes a vaccine comprising a SARS-CoV-2 spike protein (S) or portion thereof, and methods of use thereof.
1. A recombinant virus comprising a SARS-CoV-2 spike protein (S) or a portion thereof, wherein the virus is a rabies virus, a vesicular stomatitis virus (VSV), or a measles virus, and wherein the portion of the SARS-CoV-2 spike protein (S) comprises a receptor binding site of the SARS-CoV-2 spike protein (S).
2. The recombinant virus of claim 1 , wherein the virus is a rhabdovirus.
3. The recombinant virus of claim 1 , wherein the portion of the SARS-CoV-2 spike protein (S) is a S1 domain.
4. The recombinant virus of claim 1 , wherein the virus comprises a fusion protein comprising a glycoprotein (G) or portion thereof and the SARS-CoV-2 spike protein (S) or the portion thereof.
5. The recombinant virus of claim 4 , wherein the fusion protein comprises the glycoprotein (G) or portion thereof fused to a S1 domain of the SARS-CoV-2 spike protein (S).
6. The recombinant virus of claim 1 , wherein the recombinant virus is encoded by a nucleic acid molecule comprising the sequence of any one of SEQ ID NOs: 1-27.
7. A vaccine comprising the recombinant virus claim 1 , and a pharmaceutically acceptable carrier.
8. The vaccine of claim 7 , further comprising an adjuvant.
9. The vaccine of claim 8 , wherein the adjuvant is MPLA 3D(6-acyl) in 2% squalene.
10. The vaccine of claim 7 , wherein the virus is deactivated.
11. The recombinant virus of claim 1 , wherein the virus comprises the SARS-CoV-2 spike protein (S), wherein the SARS-CoV-2 spike protein (S) comprises the sequence of SEQ ID NO: 28; or a sequence comprising at least 98%, but not 100%, sequence identity to the sequence of SEQ ID NO: 28.
12. The recombinant virus of claim 6 , wherein the nucleic acid molecule comprises the sequence of SEQ ID NO: 2.